Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC.

Lung Cancer. 2014 Aug 17. pii: S0169-5002(14)00349-3. doi: 10.1016/j.lungcan.2014.08.007. [Epub ahead of print]

PMID:
25194640
[PubMed - as supplied by publisher]
2.

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers.

Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG.

J Thorac Oncol. 2014 Sep;9(9):1272-7. doi: 10.1097/JTO.0000000000000256.

PMID:
25122424
[PubMed - in process]
3.

Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.

Rimner A, Spratt DE, Zauderer MG, Rosenzweig KE, Wu AJ, Foster A, Yorke ED, Adusumilli P, Rusch VW, Krug LM.

Int J Radiat Oncol Biol Phys. 2014 Jul 26. pii: S0360-3016(14)00681-6. doi: 10.1016/j.ijrobp.2014.05.032. [Epub ahead of print]

PMID:
25073664
[PubMed - as supplied by publisher]
4.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.

Lung Cancer. 2014 Jun;84(3):271-4. doi: 10.1016/j.lungcan.2014.03.006. Epub 2014 Mar 14.

PMID:
24690410
[PubMed - in process]
5.

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M.

J Thorac Oncol. 2013 Nov;8(11):1430-3. doi: 10.1097/JTO.0b013e31829e7ef9.

PMID:
24128712
[PubMed - indexed for MEDLINE]
6.

Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

Zauderer MG, Krug LM.

Ann Cardiothorac Surg. 2012 Nov;1(4):487-90. doi: 10.3978/j.issn.2225-319X.2012.10.08. No abstract available.

PMID:
23977541
[PubMed]
Free PMC Article
7.

Important recent insights into the genetics and biology of malignant pleural mesothelioma.

McMillan R, Zauderer M, Bott M, Ladanyi M.

Ann Cardiothorac Surg. 2012 Nov;1(4):462-5. doi: 10.3978/j.issn.2225-319X.2012.10.09. No abstract available.

PMID:
23977537
[PubMed]
Free PMC Article
8.

Toxicity of initial chemotherapy in older patients with lung cancers.

Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM.

J Geriatr Oncol. 2013 Jan;4(1):64-70.

PMID:
23525607
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti F.

Clin Cancer Res. 2012 Sep 1;18(17):4485-90. doi: 10.1158/1078-0432.CCR-11-2375. Epub 2012 Jul 23.

PMID:
22825583
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, Rimner A, Flores R, Rusch V.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83. doi: 10.1016/j.ijrobp.2011.09.027. Epub 2012 May 18.

PMID:
22607910
[PubMed - indexed for MEDLINE]
11.

Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Zauderer MG, Krug LM.

J Natl Compr Canc Netw. 2012 Jan;10(1):42-7. Review.

PMID:
22223868
[PubMed - indexed for MEDLINE]
12.

The evolution of multimodality therapy for malignant pleural mesothelioma.

Zauderer MG, Krug LM.

Curr Treat Options Oncol. 2011 Jun;12(2):163-72. doi: 10.1007/s11864-011-0146-4.

PMID:
21404104
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.

Zauderer M, Krug LM, Pietanza MC, O'Rourke D.

J Thorac Oncol. 2010 Oct;5(10):1716-7. doi: 10.1097/JTO.0b013e3181f1cc32. No abstract available.

PMID:
20871272
[PubMed - indexed for MEDLINE]
14.

Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer.

Zauderer M, Patil S, Hurria A.

Breast Cancer Res Treat. 2009 Sep;117(1):205-10. doi: 10.1007/s10549-008-0116-0. Epub 2008 Jul 13.

PMID:
18622739
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Developing a cancer-specific geriatric assessment: a feasibility study.

Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB.

Cancer. 2005 Nov 1;104(9):1998-2005.

PMID:
16206252
[PubMed - indexed for MEDLINE]
Free Article
16.

Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Hurria A, Brogan K, Panageas KS, Jakubowski A, Zauderer M, Pearce C, Norton L, Howard J, Hudis C.

Drugs Aging. 2005;22(8):709-15.

PMID:
16060720
[PubMed - indexed for MEDLINE]
17.

Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Zauderer M, Howard J, Hudis C.

Breast Cancer Res Treat. 2005 Jul;92(2):151-6.

PMID:
15986124
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk